Neurosense Therapeutics Ltd. NRSN 深 沪
等待开盘 07-02 09:30:00 美东时间
0.723
+0.003
+0.42%
华盛通- 最 高0.74
- 今 开0.72
- 成交量 9.13万股
- 最 低 0.71
- 昨 收 0.72
- 总市值 2610.02万
- 52周最高 2.14
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 0.63
- 委 比 -12.50%
- 总股本 3609.98万
- 历史最高 8.18
- 量 比 0.24
- 振 幅 4.17%
- 历史最低 0.40
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial
The latest announcement is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). O...
06-25 21:50
NeuroSense Therapeutics Secures Japanese Patent 7857044 Covering Its Lead Drug Candidate For Treatment Of Amyotrophic Lateral Sclerosis
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a
06-09 21:06
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroS...
06-09 21:00
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an update. On April 28, 202...
04-29 03:57
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeu...
04-29 02:30
NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib'
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that
04-06 21:21
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6...
04-06 21:20
NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement NeuroSense received Nasdaq notices for failing to meet continued listing standards on minimum bid price, Nasdaq rule 5550(a)(2), plus market value of listed securities, Nasdaq rule 5550(b)(2). Non-compliance followed ordina
04-03 22:03
NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.35) by 25.71 percent.
03-31 21:28
NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks
NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks NeuroSense rescheduled its pre-New Drug Submission meeting with Health Canada to May 2026 to include additional clinical, biomarker, and survival analyses for PrimeC. Clinical and biomarker results from NeuroS
03-24 21:03
